Cargando…

Utilizing Predictive Inflammatory Markers for Guiding the Use of Biologicals in Severe Asthma

Asthma is a chronic respiratory disease characterized by chronic airway inflammation and airflow obstruction. Up to ten percent of asthmatics have severe asthma, and many remain uncontrolled despite optimal medical management. With our increased understanding of the heterogeneity of asthma and its c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Runnstrom, Martin, Pitner, Hilary, Xu, Jennifer, Lee, F Eun-Hyung, Kuruvilla, Merin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769207/ https://www.ncbi.nlm.nih.gov/pubmed/35068937 http://dx.doi.org/10.2147/JIR.S269297

Ejemplares similares

Reply to Liao et al.: SARS-CoV-2 mRNA Vaccine Antibody Response in Patients with Asthma Receiving Biologic Therapy: A Real-World Analysis
por: Runnstrom, Martin C., et al.
Publicado: (2022)

Patient satisfaction and utilization of telemedicine services in allergy: An institutional survey
por: Lanier, Kasey, et al.
Publicado: (2021)

Reduced COVID-19 Vaccine Response in Patients Treated with Biologic Therapies for Asthma
por: Runnstrom, Martin C., et al.
Publicado: (2022)

Reduced SARS-CoV-2 Vaccine Response in Patients Treated with Biologic Therapies for Asthma and Atopic Dermatitis
por: Runnstrom, Martin, et al.
Publicado: (2022)

Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration
por: Vanijcharoenkarn, Kristine, et al.
Publicado: (2021)

Delayed Hypersensitivity Reactions Following First Dose of the SARS-CoV2 mRNA Vaccines
por: Xu, Jennifer, et al.
Publicado: (2021)

A pragmatic guide to choosing biologic therapies in severe asthma
por: Kavanagh, Joanne E., et al.
Publicado: (2021)

Variability of Type 2 inflammatory markers guiding biologic therapy of severe asthma: A 5-year retrospective study from a single tertiary hospital()
por: Li, Hongwen, et al.
Publicado: (2021)

Value of peripheral blood eosinophil markers to predict severity of asthma
por: Casciano, Julian, et al.
Publicado: (2016)

Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era
por: Jackson, David J, et al.
Publicado: (2021)

Biological treatments for severe asthma
por: Jin, Hyun Jung
Publicado: (2020)

Biological therapy for severe asthma
por: Dragonieri, Silvano, et al.
Publicado: (2021)

Biological therapies targeting the type 2 inflammatory pathway in severe asthma (Review)
por: Fildan, Ariadna Petronela, et al.
Publicado: (2021)

Amlodipine-induced angioedema: An unusual complication of a common medication
por: Kuruvilla, Merin E., et al.
Publicado: (2018)

Symptoms and markers of symptom severity in asthma—content validity of the asthma symptom diary
por: Globe, Gary, et al.
Publicado: (2015)

Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
por: Patrawala, Meera, et al.
Publicado: (2020)

COVID-19, severe asthma, and biologics
por: García-Moguel, Ismael, et al.
Publicado: (2020)

Biologic Therapy and Severe Asthma in Children
por: Russo, Daniele, et al.
Publicado: (2021)

Biologics and airway remodeling in severe asthma
por: Varricchi, Gilda, et al.
Publicado: (2022)

Switching Biological Therapies in Severe Asthma
por: Scioscia, Giulia, et al.
Publicado: (2023)

Inflammatory phenotypes of severe asthma in India
por: Dasgupta, Angira, et al.
Publicado: (2019)

Inflammatory Remission in T2 Severe Asthma
por: Rial, Manuel J., et al.
Publicado: (2022)

COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry
por: Hanon, Shane, et al.
Publicado: (2020)

Leptin, ghrelin and calprotectin: inflammatory markers in childhood asthma?
por: Cobanoglu, Nazan, et al.
Publicado: (2013)

Nonadherence in the era of severe asthma biologics and thermoplasty
por: Lee, Joy, et al.
Publicado: (2018)

Molecular Targets for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Novel Biological Therapies for Severe Asthma Endotypes
por: Pelaia, Corrado, et al.
Publicado: (2022)

Biological Therapy of Severe Asthma and Nasal Polyps
por: Bakakos, Agamemnon, et al.
Publicado: (2022)

COVID-19, Eosinophils, and Biologicals for Severe Asthma
por: Lombardi, Carlo, et al.
Publicado: (2022)

Severe Asthma in the Era of Biologics: Continuous Challenges
por: Schoini, Pinelopi, et al.
Publicado: (2023)

Severe Asthma and Biological Therapies: Now and the Future
por: Sardon-Prado, Olaia, et al.
Publicado: (2023)

The Role of Mast Cells in Aspirin-Exacerbated Respiratory Disease (AERD) Pathogenesis: Implications for Future Therapeutics
por: Kuruvilla, Merin E, et al.
Publicado: (2020)

The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia
por: Duman, Dildar, et al.
Publicado: (2015)

Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation
por: Ismael, Media N., et al.
Publicado: (2019)

Interleukins and inflammatory markers are useful in predicting the severity of acute pancreatitis
por: Ćeranić, Davorin Branislav, et al.
Publicado: (2020)

Prediction of Asthma Exacerbations in Children by Innovative Exhaled Inflammatory Markers: Results of a Longitudinal Study
por: van Vliet, Dillys, et al.
Publicado: (2015)

Differential serum protein markers and the clinical severity of asthma
por: Meyer, Norbert, et al.
Publicado: (2014)

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
por: Crimi, Claudia, et al.
Publicado: (2023)

Utility of warning signs in guiding admission and predicting severe disease in adult dengue
por: Leo, Yee-Sin, et al.
Publicado: (2013)

Emergent Inflammatory Markers and Echocardiographic Indices in Patients with Bronchial Asthma
por: Gkavogiannakis, Nikolaos A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pd6t83doudbof62s995n6klrrs